research use only

Baricitinib phosphate JAK inhibitor

Cat.No.S5754

Baricitinib phosphate (INCB-028050, LY-3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19.
Jump to

Quality Control

Batch: Purity: 99.99%
99.99

Solubility

In vitro
Batch:

DMSO : 94 mg/mL (200.25 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 469.41 Formula

C16H20N7O6PS

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1187595-84-1 -- Storage of Stock Solutions

Synonyms INCB-028050 phosphate, LY-3009104 phosphate SMILES CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
JAK2
(Cell-free assay)
5.7 nM
JAK1
(Cell-free assay)
5.9 nM
TYK2
(Cell-free assay)
53 nM
JAK3
(Cell-free assay)
>400 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-04)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07222137 RECRUITING
Diabetes Mellitus, Type 1
Eli Lilly and Company
2026-01-12 PHASE3
NCT03773965 RECRUITING
Juvenile Idiopathic Arthritis
Eli Lilly and Company
2019-04-05 PHASE3
NCT06923072 RECRUITING
Kohlmeier-Degos Disease; Malignant Atrophic Papulosis; Degos Disease; Papulosis, Malignant Atrophic
National Heart, Lung, and Blood Institute (NHLBI)
2026-02-18 PHASE2
NCT07543458 NOT_YET_RECRUITING
Dengue; Severe Dengue; Mosquito-Borne Diseases; Vector Borne Diseases; Arbovirus Infections; Flavivirus Infections; RNA Virus Infections; Hemorrhagic Fever
Oxford University Clinical Research Unit, Vietnam
2026-10-01 PHASE3
NCT07262983 RECRUITING
Hyper IgE Syndrome From STAT3 Mutation; Job s Syndrome; HIES; Lupus; Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
2026-09-09 PHASE1
NCT07003997 RECRUITING
Major Depressive Disorder
Emory University
2025-09-03 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map